Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Serine racemase is required for colorectal tumor growth and a potential therapeutic target.

ABSTRACT: Serine racemase (SRR) is an enzyme that catalyzes two reactions, the racemization and the dehydration of L-Ser and D-Ser and has been studied mainly in the fields of central nervous system. The function of SRR in cancer metabolism has not been elucidated. Here we show that SRR expression is upregulated in colorectal adenoma and adenocarcinoma lesions compared to non-neoplastic mucosa in human colorectal cancer specimens. Further analysis by using CRISPR/CRISPR-associated protein 9 system reveals that SRR enhances colorectal cancer cell proliferation via maintaining intracellular pyruvate and mitochondrial mass resulting in higher basal reactive oxygen species level, and has anti-apoptotic function.

ORGANISM(S): Homo sapiens

PROVIDER: GSE128804 | GEO | 2020/01/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genetic inactivation of serine racemase produces behavioral phenotypes related to schizophrenia in mice

Project description:Abnormal N-methyl-D-aspartate receptor (NMDAR) function has been implicated in the pathophysiology of schizophrenia. D-serine is an important NMDAR modulator, and to elucidate the role of the D-serine synthesis enzyme serine racemase (Srr) in schizophrenia, we identified and characterized mice with an ENU-induced mutation that results in a complete loss of Srr activity and drastically reduced D-serine levels. Mutant mice displayed behaviors relevant to schizophrenia, including impairments in prepulse inhibition, sociability and spatial discrimination. Behavioral deficits were rescued by D-serine and the atypical antipsychotic clozapine, and were conversely, amplified by NMDAR inhibition. Expression profiling revealed that the Srr mutation influenced several genes that have been linked to schizophrenia and cognitive ability. Furthermore, analysis of Srr genetic variants in humans identified a robust association with schizophrenia. This study demonstrates that aberrant serine racemase function and diminished D-serine may contribute to schizophrenia pathogenesis, and that D-serine may be a beneficial form of treatment Keywords: genetic-mutant vs. wildtype comparison

2009-09-05 | GSE13974 | GEO

mRNA expression data from adenoma, gene modified, and colorectal cancer organoid.

Project description:We established human colorectal tumor organoids from benign adenoma, primary colorectal cancer or metastasized colorectal cancer. The gene signature of tumor organoids associated with their tumor progression status. We also generated genome-edited organoids from human intestinal organoids recapitulating adenoma-carcinoma sequence. Gene expression signature of the genome engineered organoids were similar to that of adenoma organoids. This result indicated multiple (up to five) genetic mutations were insufficient for gene expression reprogramming of colorectal cancer. We used microarrays to detail the global program of gene expression in human colorectal tumor organoids and artificially mutation introduced organoids. To assess the expression profiling of genome-engineered organoids, we prepared total-RNA from cultured adenoma, carcinoma and genome-engineered organoids. We produced two types of genome-engineered organoids using the CRISPR/Cas9 or lentivirus vector system. Each engineered gene and engineered methods are described as a single alphabet and method name, respectively, in the sample characteristics field. The abbreviations for the engineered genes are as follows. 1) Genome-engineered organoids with CRISPR/Cas9 A = APC deletion; K = KRAS G12V knock in; S = Smad4 deletion; T = TP53 deletion; P = PIK3CA E545K knock in. 2) Genome-engineered organoids with Lent virus vector B = CTNNB1 S33Y overexpression; K = KRAS G12V overexpression; S = Smad4 shRNA overexpression; T = TP53 shRNA overexpression; P = PIK3CA E545K overexpression.

2015-01-18 | E-GEOD-57965 | biostudies-arrayexpress

mRNA expression data from adenoma, gene modified, and colorectal cancer organoid.

2015-01-18 | GSE57965 | GEO

Human colorectal adenomas and cancer

Project description:human blood plasma proteomes of colorectal adenoma, colorectal cancer and control patients

2019-10-01 | PXD007844 | JPOST Repository

Genomic studies of colorectal polyps and concurrent cancer

Project description:The well-known colorectal adenoma-carcinoma sequence suggests that a normal epithelial cell, through accumulations of genetic lesion and epigenetic disregulation can transform into a benign adenoma then further develop into a cancer. Using microarray-based comparative genomic hybridization (CGH), we reveal genome-wide copy number variations in colorectal cancer and polyp and use them to determine the tissueM-^Rs clonal relationship.

2011-06-30 | E-MEXP-3149 | biostudies-arrayexpress

Human Transcriptome Array 2.0 (HTA) from healthy colonic, colorectal adenoma and colorectal cancer tissue

Project description:Whole transcriptome expression levels of healthy colonic, colorectal adenoma and colorectal cancer biopsy samples were analyzed by HTA 2.0 microarrays

2019-09-13 | GSE100179 | GEO

Serine racemase is required for colorectal tumor growth and a potential therapeutic target.

Project description:Serine racemase is required for colorectal tumor growth and a potential therapeutic target.

| PRJNA528919 | ENA

Transcription profiling of adenoma and corresponding normal mucosa in human colorectal cancer cases

Project description:The differences in gene expression profile between adenoma and corresponding normal mucosa in colorectal cancer cases.

2005-05-20 | E-MEXP-341 | biostudies-arrayexpress

Identification of candidate microRNAs in colorectal adenomas and adenocarcinomas

Project description:We showed that some microRNAs could be characteristic of the progression from adenoma to adenocarcinoma in colorectal cancer.

2013-08-30 | GSE50194 | GEO

Global DNA methylation alterations reveal multiple pathways in the initiation and progression of colorectal cancer

Project description:Genetic and epigenetic alterations are a fundamental aspect of colorectal cancer formation. There is considerable heterogeneity between colorectal cancers regarding the mutations and methylated genes they carry, and this heterogeneity may arise early in the polyp-cancer sequence. However, our understanding of the epigenetic alterations and gene mutations in colon adenomas and their relation to colorectal cancer is incomplete. Thus, we have assessed the methylome in normal colon mucosa, tubular adenomas, and colorectal adenocarcinomas and have determined the relationship of these findings between adenomas and cancer in the colon. Genome-wide alterations in DNA methylation were found in the normal colon mucosa adjacent to colorectal cancer, tubular adenomas, and colorectal cancer. Three subgroups of CRCs and two subgroups of adenomas were identified on the basis of their DNA methylation patterns. The adenomas separated into a high-frequency methylation class (Adenoma-H) and a low-frequency methylation class. The adenoma-H polyps have a methylated DNA signature similar to non-CIMP CRCs, whereas those of the Adenoma-L class have a similar methylation pattern to normal colon mucosa. The CpGs that account for these signatures are located in intragenic/intergenic regions, which suggests that these two groups of adenomas arise from different stem cell populations. We conducted genome-wide array-based studies and comprehensive data analyses of aberrantly methylated loci in 41 normal colon samples, 42 colon adenomas, and 64 colorectal cancers. Supplementary file 'GSE48684_Matrix_signal_intensities_1.txt.gz': includes the unmethylated and methylated signal intensities from Samples GSM1183439-GSM1183561. Supplementary file 'GSE48684_Matrix_signal_intensities_2.txt.gz': includes the unmethylated and methylated signal intensities from Samples GSM1235135-GSM1235158.

2014-09-08 | E-GEOD-48684 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data